Alcolase Raises €1.5M for Enzyme Alcohol Intolerance Treatment

Copenhagen-based biotech innovator Alcolase has successfully closed a €1.5 million seed funding round, aiming to revolutionize the management of alcohol intolerance. The investment was co-led by Ada Ventures and saw participation from Delphinus Venture Capital, Antler, Manigoff Invest, and a cohort of private investors. This capital infusion will accelerate the development of Alcolase's proprietary enzyme system, designed to mitigate the physiological effects of alcohol consumption for individuals with sensitivities.

The core of Alcolase's innovation lies in a novel liposomal encapsulation technology. This advanced delivery mechanism is engineered to shield its active enzymes from the harsh acidic environment of the stomach, ensuring they remain viable and functional within the digestive tract. The goal is to enable the breakdown of alcohol before it is absorbed into the bloodstream, thereby reducing or eliminating common adverse reactions like flushing and nausea experienced by those with conditions such as ALDH2 deficiency.

This deficiency, prevalent in an estimated 540 million people, primarily across East Asia, presents significant social and health challenges. Ada Ventures highlighted that the issue transcends mere physical discomfort, impacting social interactions and professional engagements where alcohol consumption is customary. The firm's investment aligns with its strategic focus on the healthy ageing sector, targeting scientific advancements that address substantial, yet often overlooked, global health needs.

The scientific pedigree of Alcolase's leadership team was a key draw for investors. CEO Mikkel Precht brings a background in Molecular Biomedicine, while co-founder Ib Christensen possesses deep expertise in fermentation and purification, with prior experience at pharmaceutical giants like Novo Nordisk, Boehringer Ingelheim, and Xellia Pharmaceuticals. Chief Scientific Officer Henrik Almblad leads the enzyme engineering efforts, holding advanced degrees in Infectious Disease and Immunology, and Human Biology.

Alcolase's strategic approach includes establishing a UK therapeutic subsidiary to leverage the nation's life sciences ecosystem for broader platform development. The company has already garnered early commercial interest, evidenced by letters of intent from prominent Asian pharmaceutical and food technology firms, including a major enzyme producer. This commercial validation, coupled with support from the Korean government and strong consumer interest data indicating a willingness to pay a premium for effective solutions, underpins the company's market entry strategy.

The company intends to debut its initial product in Singapore, followed by an expansion into South Korea, capitalizing on markets with high prevalence of alcohol intolerance and significant consumer demand. The newly secured funding will be instrumental in advancing in vivo studies, bolstering intellectual property, scaling the UK operations, and driving commercialization efforts in these key launch territories. Alasdair Thong, Venture Partner at Ada Ventures, will join the Alcolase board, providing strategic guidance.